Immune escape is a fundamental trait of cancer in which mechanistic knowledge is incomplete. Here, we describe a novel mechanism by which hypoxia contributes to tumoral immune escape from cytotoxic T lymphocytes (CTL). Exposure of human or murine cancer cells to hypoxia for 24 hours led to upregulation of the immune inhibitory molecule programmed cell death ligand-1 (PD-L1; also known as B7-H1), in a manner dependent on the transcription factor hypoxia-inducible factor-1a (HIF-1a). In vivo studies also demonstrated cellular colocalization of HIF-1a and PD-L1 in tumors. Hypoxia-induced expression of PD-L1 in cancer cells increased their resistance to CTL-mediated lysis. Using glyceryl trinitrate (GTN), an agonist of nitric oxide (NO) signaling known to block HIF-1a accumulation in hypoxic cells, we prevented hypoxiainduced PD-L1 expression and diminished resistance to CTL-mediated lysis. Moreover, transdermal administration of GTN attenuated tumor growth in mice. We found that higher expression of PD-L1 induced in tumor cells by exposure to hypoxia led to increased apoptosis of cocultured CTLs and Jurkat leukemia T cells. This increase in apoptosis was prevented by blocking the interaction of PD-L1 with PD-1, the PD-L1 receptor on T cells, or by addition of GTN. Our findings point to a role for hypoxia/HIF-1 in driving immune escape from CTL, and they suggest a novel cancer immunotherapy to block PD-L1 expression in hypoxic-tumor cells by administering NO mimetics. Cancer Res; 74(3); 1-10. Ó2013 AACR.
Introduction
An important feature of malignant progression is the selection of tumor cell variants that are capable of escaping detection and destruction by the innate and adaptive arms of the immune system (1) . There is evidence that tumor cells can escape from adaptive immunity by increasing their surface expression of inhibitory B7 costimulatory molecules (2, 3) . These cell surface molecules are members of a family of activating and inhibitory costimulatory ligands with important roles in the regulation of CTL responses (3) . A member of this family of molecules, programmed cell death ligand-1 (PD-L1, also known as B7-H1), is expressed in human and rodent tumors to provide negative signals that suppress CTL responses.
PD-L1 interacts with the programmed cell death-1 (PD-1) receptor on activated CTLs to inhibit immune responses via mechanisms that include induction of apoptosis and anergy in the CTLs (4) . Although the mechanisms regulating PD-L1 expression have not been fully elucidated, interferon-g (IFN-g) was shown to stimulate the expression of PD-L1 in cancer cell lines (5) . In addition, signaling via phosphatase and tensin homolog/phosphatidylinositol-3-kinase (PTEN/ PI3K) was linked to the posttranscriptional regulation of PD-L1 expression (6) . Interleukin (IL)-10, VEGF, activation of Toll-like receptor-4, and signaling via extracellular signalregulated kinase, were also reported to increase PD-L1 expression (7) (8) (9) .
Many studies have demonstrated the important contribution of hypoxia to the acquisition of malignant properties in cancer cells such as drug resistance (10) and metastatic ability (11) (12) (13) ; however, the effect of hypoxia on tumor immune escape remains poorly understood. We previously showed that exposure of tumor cells to hypoxia increases their intrinsic resistance to lysis mediated by innate immune effector cells (14, 15) . In the present study, we investigated whether exposure of tumor cells to hypoxia increases their resistance to adaptive (T cell-mediated) immunity. We report here that hypoxia increases the expression of PD-L1 in human breast and prostate cancer cells, as well as in mouse melanoma and mammary carcinoma cells, and that increased expression of these inhibitory molecules leads to resistance to CTL-mediated lysis.
Materials and Methods

Cell lines
Human MDA-MB-231 breast cancer cells, human DU145 prostatic carcinoma cells, human Jurkat leukemia T cells, and mouse B16-F10 melanoma and 4T1 mammary carcinoma cells were obtained from the American Type Culture Collection.
MDA-MB-231 and DU145 cells were cultured in RPMI 1640 medium (Invitrogen) supplemented with 5% FBS, whereas Jurkat cells were cultured in RPMI 1640 medium supplemented with 10% FBS. Mouse B16-F10 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS. Mouse B16-OVA melanoma cells were kindly provided by Dr. Scott A. Gerber (University of Rochester Medical Center, Rochester, NY), and were maintained in RPMI 1640/ 10% FBS medium supplemented with G418 (100 mg/mL). The authenticity of these cell lines has not been verified in the last six months. All experiments were conducted using cultures not exceeding 60% to 70% confluence to avoid pericellular hypoxia induced by overconfluence.
Blocking antibodies
To block human PD-L1 or PD-1 function, we used antihuman PD-L1 antibody (4 mg/mL; BioLegend; Cat. #329702) or anti-human PD-1 (2 mg/mL; R&D Systems; Cat. #AF1086). To block mouse PD-L1 or PD-1 (CD279), we used anti-mouse PD-L1 antibody (2 mg/mL; eBiosciences; Cat. #16-5982-81) or antimouse PD-1 antibody (anti-CD279; 1 mg/mL; BD Pharmingen; Cat. #551891), respectively.
mRNA knockdown
Knockdown of human hypoxia-inducible factor-1a (HIF-1a) or PD-L1 (CD274) expression was achieved using Silencervalidated siRNA #42840 or Silencer Select siRNA #s26547 (Ambion Inc.), respectively. To knock down mouse PD-L1 (CD274) or mouse HIF-1a, we used Silencer Select siRNA #s82016 or #s67530 (Ambion Inc.), respectively. Silencer Negative Control siRNA #2 (Ambion Inc.) was used as control. The siRNA (25 nmol/L final concentration) was introduced into cells using siPORT NeoFx reagent (Ambion Inc.) according to the manufacturer's instructions. Treatments with siRNA were performed 24 hours before incubation in hypoxia or standard conditions.
Exposure to different levels of oxygen
Tumor cell cultures were incubated under control (20% O 2 ) or hypoxic (0.5% O 2 ) conditions for 24 hours as described previously (15 C for 20 seconds, 72 C for 20 seconds. Cellular HIF-1a and PD-L1 protein levels were determined in total cell extracts by Western blot analysis. Antibodies used included monoclonal mouse anti-human PD-L1 antibody (1/250 dilution; R&D Systems; MAB156), rat anti-mouse PD-L1 antibody (1/250 dilution; eBiosciences; 14-5982-82), and monoclonal mouse anti-human HIF-1a antibody (1/250 dilution; BD Biosciences; # 610958). Membranes were probed for b-actin or a-tubulin to control for differences in the loading of the gels. Corresponding bands were detected by enhanced chemiluminescence. Alternatively, surface PD-L1 levels were measured in B16-OVA cells by flow cytometry using rat antimouse PD-L1 antibody (eBiosciences; #14-5982-82) and a standard protocol.
Overexpression of HIF-1a in MDA-MB-231 cells
Plasmid DNA (either pCMV6-kan/neo empty vector or pCMV6-kan/neo vector expressing nonmutant HIF-1a; generously provided by Dr. Lynne Postovit, Department of Oncology, University of Alberta, Edmonton, Canada) was introduced into MDA-MB-231 cells at a concentration of 2.5 mg/well using Lipofectamine 2000 (5 mL/well; Invitrogen). Following a 24-hour incubation in 20% O 2 , the medium was replaced and cells were allowed to recover for another 24 hours. Cells were then harvested, lysed, and the protein was extracted and used for Western blot analysis.
Identification of HIF-1a-binding sites in PD-L1
Canonical hypoxia response elements (HRE; TACGTG) within genomic sequences of PD-L1 were first identified using the Ensembl genome browser (URL: http://useast.ensembl. org/index.html). þ CTLs for a further 24 hours. T lymphocytes were also incubated in the absence of other cells under hypoxic or control conditions to determine the potential effects of hypoxia alone on apoptosis as determined below. Expression of surface PD-1 in CD3 þ peripheral blood lymphocytes and Jurkat leukemia T cells was determined by flow cytometry using phycoerythrin-labeled anti-human PD-1 (CD279) antibody (eBiosciences; Cat. #12-9969).
Generation of tumor-specific CTLs and cytotoxicity assay
To determine whether hypoxia induces resistance of tumor cells to adaptive immunity, we performed cytotoxicity assays using primed mouse CD3
þ CTLs as effectors and B16-OVA or B16-F10 melanoma cells as targets, both of which express PD-L1 (16) . To generate tumor-specific CTLs from precursor T cells in vivo, we followed a well-established protocol (17) . Briefly, female C57Bl/6 mice (6-8 weeks old; The Jackson Laboratory) were injected intraperitoneally with 5 Â 10 6 mitomycin Ctreated B16-OVA melanoma cells. Fourteen days later, mice were euthanized and their spleens were removed and passed through a fine wire mesh in order to obtain single-cell suspensions. Following lysis of red blood cells, CD3 þ lymphocytes were isolated from the primed splenic lymphocytes using magnetic microbeads coated with anti-mouse CD3 antibody (Miltenyi Biotec; Cat. #130-095-130). CD3 þ lymphocytes were expanded by coculture for five days with mitomycin C-treated B16-OVA cells, at a ratio of 5:1, using sensitization medium (RPMI-10 medium containing 1 mmol/L sodium pyruvate and Â1 nonessential amino acids) in the presence of recombinant IL-2 (Sigma-Aldrich; Cat. # SRP3085; 30 U/mL). Cytotoxicity was assessed by means of a LIVE/DEAD cell viability/cytotoxicity assay (Invitrogen) as we reported previously (15) .
Flow cytometric assessment of apoptosis Extent of apoptosis in CD3
þ CD8 þ lymphocytes from coculture studies was determined by two-color flow cytometry using FITC-Annexin V (5 mL/test; BD Biosciences; #556420) as well as anti-human CD8 þ phycoerythrin (PE)-tagged antibody (BD Biosciences; #555635). For determination of Jurkat cell apoptosis, an apoptosis detection kit APO-BRDU (BD Biosciences; # 556405) was used. All flow cytometric analyses were performed using a Beckman Coulter EPICS Altra HSS flow cytometer (Beckman-Coulter Tumor growth study Female Balb/c mice (6-8 weeks old; The Jackson Laboratory) were inoculated orthotopically in the left mammary fat pad with 3.5 Â 10 3 syngeneic 4T1 cells in 100 mL of PBS. When the tumors reached a palpable size (50-100 mm 3 ), mice were randomly divided in two groups: (i) 24 mice treated with 0.25 cm 2 Minitran transdermal patches (3M Pharmaceuticals) delivering 1.8 mg of GTN per hour and placed on the back of the neck and (ii) 17 mice treated with transdermal placebo patches. Tumor volumes were measured every two days using digital calipers. The formula used to calculate tumor volume was length Â width 2 divided by 2.
Statistical analysis
GraphPad Prism software (GraphPad Software, Inc.) was used for all statistical analyses. For flow cytometry, expression was presented as percentage of positive cells, and analyzed by one-way ANOVA followed by the Bonferroni multiple comparison test. The relative means of immunoblot densitometric values were calculated (compared with a-tubulin or b-actin) and analyzed using one-way ANOVA followed by the Bonferroni' multiple comparison test. Differences were considered to be statistically significant at P < 0.05. Cytotoxicity results were analyzed by one-way ANOVA of the Y-intercepts of the linear regressions of killing curves pooled from different experiments, followed by the Bonferroni multiple comparison test to determine whether differences between individual treatment groups reached statistical significance. Two-way ANOVA followed by the Bonferroni multiple comparison test was used to determine statistical differences between cytolytic activities at individual effector-to-target ratios as well as to determine differences in 4T1 tumor growth. (Fig. 1B) . This correlation persisted even in some experiments in which HIF-1a levels were unusually high in cultures incubated in 20% O 2 . Also, when HIF-1a was overexpressed in 20% O 2 in MDA-MB-231 cells transfected with a cDNAencoding HIF-1a, PD-L1 protein expression was significantly upregulated (P < 0.01; Supplementary Fig. S1 ).
Results and Discussion
We then determined by immunofluorescence whether HIF1a and PD-L1 colocalize in vivo in a mouse tumor model. Mouse 4T1 mammary carcinoma cells were injected orthotopically into the mammary fat pad of syngeneic Balb/c female mice and allowed to form tumors. Earlier results had revealed that PD-L1 mRNA expression was upregulated by hypoxia in these cells and that this upregulation was prevented when HIF1a was knocked down (Supplementary Fig. S2A ). Results demonstrated cellular colocalization of HIF-1a (nuclear) and PD-L1 (mostly cytoplasmic) in 4T1 tumors ( Supplementary  Fig. S2B ).
To determine whether HIF-1a interacts with PD-L1 genomic sequences, we conducted ChIP assays using primer sequences flanking two potential HIF-1a HREs located within the PD-L1 gene. Results of standard and qRT-PCR revealed that HIF-1a binds to HRE2 (see Materials and Methods section) in the intron located between exons 4 and 5 of the PD-L1 genomic sequences in both DU145 and MDA-MB-231 cells ( Fig. 1C ; see legend for details). The second canonical sequence (HRE1) did not exhibit detectable binding of HIF-1a (data not shown; see Materials and Methods section). To confirm that HIF-1a is indeed required for the hypoxia-induced expression of PD-L1, we conducted HIF-1a knockdown experiments using validated siRNA. Knockdown of HIF-1a expression with siRNA prevented HIF-1a protein accumulation in DU145 cells incubated in 0.5% O 2 for 24 hours ( Supplementary Fig. S2C ) and inhibited the hypoxiamediated increase in PD-L1 mRNA and cell surface protein levels (determined by flow cytometry) in human DU145 cells and mouse B16-OVA cells, respectively ( Fig. 1D and Supplementary Fig. S2D ). Together, these findings demonstrate that hypoxia increases PD-L1 expression in tumor cells via a mechanism dependent on HIF-1a.
Hypoxia increases resistance to CTL-mediated lysis in tumor cells via a mechanism dependent on HIF-1a, PD-L1, and PD-1
To further investigate the relevance of hypoxia-induced expression of PD-L1 to tumor cell escape from adaptive immunity, we used in vivo/ex vivo-generated CTLs as effectors against B16-OVA cells in cytolytic assays performed in vitro (Fig. 2) . B16-OVA cells express high levels of chicken ovalbumin (OVA) on the surface. Therefore, immunization of C57Bl/6 mice with mitomycin C-treated B16-OVA cells results in the expansion of OVA-specific CTLs. Additional in vitro priming of CD3 þ CTLs isolated from spleens of immunized mice led to further proliferation of lymphocytes with cytolytic activity against OVA-expressing cells. Thus, we tested the cytolytic activity of these CD3 þ CTLs using as targets B16-OVA cells preincubated in hypoxia or standard conditions. To account for nonspecific, OVA-independent, cytolytic activity in the expanded splenic lymphocyte population, we also conducted control assays using B16-F10 melanoma cells that do not express ovalbumin. As previously reported (18) (19) (20) , there was some nonspecific cytolytic activity of CD3 þ CTLs against B16-F10 cells that was also independent of hypoxia ( Supplementary  Fig. S3A ). This nonspecific cytolytic activity at each effector: target ratio was subtracted from the cytolytic activity at corresponding effector:target ratios in assays using B16-OVA cells as targets in order to determine OVA-specific cell killing (Fig. 2) . The total cytolytic activity curves, which include specific and nonspecific cell killing, are provided in Supplementary Fig. S3B-S3E .
To determine a potential role of HIF-1a, PD-L1, and PD-1 in hypoxia-induced resistance to CTL-mediated lysis, we used the siRNA knockdown approach (for HIF-1a and PD-L1) as well as blocking antibodies (for PD-L1 and PD-1). Before performing the cytotoxicity assays, we confirmed siRNA-mediated knockdown of PD-L1 expression in B16-OVA cells (Supplementary Fig. S4A ). Cytotoxicity assays revealed that hypoxic (0.5% O 2 ) preincubation of B16-OVA cells, either transfected with control siRNA or preincubated with control immunoglobulin G (IgG), resulted in a significant decrease in CTL-mediated lysis (percent killing) when compared with preincubation in 20% O 2 ( Fig. 2A-D) . This effect of hypoxia on resistance to CTL-mediated lysis did not occur in OVA-negative B16-F10 melanoma cells, which were significantly (P < 0.001) more resistant to CTL-mediated lysis than the B16-OVA cells (Supplementary Fig. S3A ). This finding indicates that the hypoxia-induced resistance to lysis in B16-OVA cells is due to reduced killing by OVAspecific CD3
þ CTLs. Knockdown of HIF-1a or PD-L1 with siRNA in B16-OVA cells abolished the hypoxia-induced (Continued.) For these experiments, both cell lines were transfected with either scrambled control siRNA or HIF-1a siRNA before exposure to either 20% or 0.5% O2. Graphs in D represent pooled data from three to five experiments. A representative flow cytometry histogram indicating the effect of hypoxia and HIF-1a knockdown on PD-L1 expression in B16-OVA cells is shown in Supplementary Fig. S2D . Results of flow cytometry showed a 19% AE 2% increase in the PD-L1 mean fluorescence intensity (P < 0.01) in control siRNA-transfected B16-OVA cells incubated in 0.5% O2 versus 20% O2. This effect of hypoxia was abrogated in cells transfected with HIF-1a siRNA (data not shown). Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001.
resistance to CTL-mediated killing ( Fig. 2A and B) . Similarly, incubation of B16-OVA cells with either PD-L1 or PD-1 blocking antibodies resulted in inhibition of hypoxiainduced resistance to CTL-mediated lysis ( Fig. 2C and D) . Results of two-way ANOVA of the mean cytolytic activities at each individual effector-to-target ratio are shown in Supplementary Table S1 . Together, these results indicate that the resistance to CTL-mediated lysis in B16-OVA cells exposed to hypoxia requires the expression of functional HIF-1a, PD-L1, and PD-1. On the basis of our results showing that hypoxia increases PD-L1 expression in a manner dependent on HIF-1a (Fig. 1D) , we propose that the hypoxia-induced resistance to CTL-mediated lysis in B16-OVA cells is a result of increased interaction between PD-L1 on the tumor cells and PD-1 on the CTLs.
GTN inhibits the hypoxia-induced upregulation of PD-L1 expression and the hypoxia-induced resistance to CTLmediated lysis
We previously reported that the hypoxia-induced accumulation of HIF-1a protein could be prevented by incubating DU145 cells in the presence of low concentrations of the nitric oxide (NO) mimetic GTN or 8-bromo-cGMP, an activator of classical NO signaling (15) . Incubation of DU145, MDA-MB-231, or B16-OVA cells in the presence of GTN (10 nmol/L) for 24 hours blocked the hypoxia-induced upregulation of PD-L1 expression at the mRNA and protein levels as determined by qRT-PCR and Western blotting (Fig. 3A-C) . Moreover, incubation of B16-OVA cells in the presence of GTN (10 nmol/L) resulted in inhibition of hypoxia-induced resistance to CTLmediated lysis (Fig. 3D) . These results point to a potential Fig. S4B ).
Hypoxia induces T-cell apoptosis by upregulating PD-L1 expression in tumor cells
Interactions between PD-L1 on tumor cells and PD-1 on T cells are known to lead to anergy or apoptosis in the T cells (4) .
To further elucidate the mechanism by which hypoxia-induced upregulation of PD-L1 expression leads to tumor-cell resistance to CTL-mediated lysis, we determined the effect of PD-L1 upregulation in tumor cells on T-cell apoptosis. Specifically, we measured apoptosis (Annexin V or apo-BrDU labeling) in Jurkat leukemia T cells or peripheral blood human CD3 þ lymphocytes incubated either alone or in coculture with DU145 cells (Fig. 4A and B Fig. 4A and  B ). When cocultured with DU145 cells in 0.5% O 2 , the apoptotic index of T cells (see Materials and Methods section) increased substantially ( Fig. 4A and B) . Incubation of the cocultures in the presence of GTN, PD-L1 blocking antibody, or PD-1 blocking antibody significantly attenuated the extent of apoptosis induced by hypoxia ( Fig. 4A and B) . We confirmed by flow cytometry the expression of PD-1 in Jurkat cells and CD8 þ peripheral blood lymphocytes. Compared with CD3 þ peripheral blood lymphocytes, a higher number of Jurkat cells expressed surface PD-1 (91.3% vs. 8.1%; Fig. 4C ), which paralleled the levels of apoptosis in these T cells induced by the hypoxic tumor cells ( Fig. 4A and B (Fig. 4C) . Furthermore, preincubation of DU145 cells in hypoxia in the presence of GTN or PD-L1 blocking antibody inhibited the proapoptotic effect of hypoxic DU145 cells on T cells (Fig. 4C) . These results reveal that hypoxia may contribute to cancer immune evasion by inducing CTL apoptosis through a pathway involving increased tumor cell PD-L1 expression. Our results show that this pathway is dependent on HIF-1a and that it can be inhibited by GTN. These findings reveal a novel mechanism of escape from adaptive immunity operating in tumor cells exposed to hypoxia. Together with our previous studies showing that hypoxia contributes to tumor cell escape from innate immunity (14, 15) , the results of the present study provide evidence that hypoxia also contributes to a key phase of cancer immunoediting, i.e., escape from adaptive immunity (1), thereby promoting malignant progression. Thus, targeting specific steps in these mechanisms of immune escape-for example, through the use of NO mimetics such as GTN or small molecule inhibitors-could lead to novel immunotherapeutic strategies. 
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